rss
Br J Ophthalmol 2003;87:1206-1211 doi:10.1136/bjo.87.10.1206
  • Clinical science
    • Scientific reports

Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis

  1. M Kidd1,
  2. S H McKenzie2,
  3. I Steven2,
  4. C Cooper1,
  5. R Lanz3,
  6. the Australian Ketotifen Study Group*
  1. 1The University of Sydney, Department of General Practice, Sydney, NSW, Australia
  2. 2Royal Australian College of General Practitioners, Sydney, NSW, Australia
  3. 3Novartis Ophthalmics AG, Bülach, Switzerland
  1. Correspondence to: Professor Michael Kidd, The University of Sydney, Department of General Practice, Sydney, NSW, Australia; michael.kidd{at}med.usyd.edu.au
  • Accepted 20 January 2003

Abstract

Background: Ketotifen blocks histamine H1 receptors, stabilises mast cells, and prevents eosinophil accumulation. These multiple, pharmacological mechanisms provided the rationale for assessing the efficacy and safety of ketotifen 0.025% eye drops in subjects with seasonal allergic conjunctivitis (SAC) in an environmental setting.

Methods: This was a double masked, randomised, multicentre trial conducted in Australia. Subjects were randomly assigned to ketotifen fumarate 0.025% ophthalmic solution, placebo (as vehicle), or levocabastine hydrochloride 0.05% ophthalmic suspension, twice daily in each eye for a 4 week period. Subjects were assessed at follow up (days 5–8) and termination (days 25–31) visits. The primary efficacy variable was the responder rate, based on the subjects’ assessment of global efficacy at the follow up visit.

Results: 519 subjects were randomised to treatment. At the follow up visit, the responder rate, based on subjects’ assessment of global efficacy, was significantly greater in the ketotifen group (49.5%) than in the placebo group (33.0%) for subjects with a positive diagnostic test for pollen allergy (p = 0.02). The investigators’ assessment of responder rates also showed that ketotifen was superior to placebo (p = 0.001). Ketotifen produced a significantly better outcome than levocabastine (p<0.05) for relief of signs and symptoms of SAC, at both the follow up and the termination visit. The type and frequency of adverse events were similar across treatment groups.

Conclusions: In an environmental setting, ketotifen fumarate 0.025% ophthalmic solution was well tolerated and effective in reducing the signs and symptoms of SAC, and in preventing their recurrence. Ketotifen consistently showed the best efficacy in comparison with both placebo and levocabastine. These results indicate that ketotifen eye drops are a valuable treatment option for this condition.

Footnotes

  • ↵* All participating Centres are listed at the end of the manuscript

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.